Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

Breakthroughs in the development of highly accurate fluid and neuroimaging biomarkers
have catalysed the conceptual transformation of Alzheimer disease (AD) from the traditional …

Blood biomarkers indicative of Alzheimer's disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …

Background Trials of monoclonal antibodies that target various forms of amyloid at different
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …

A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's
disease are needed to facilitate the initial screening process of participants in disease …

Importance Alzheimer disease (AD) pathology starts with a prolonged phase of β-amyloid
(Aβ) accumulation without symptoms. The duration of this phase differs greatly among …

Importance Disrupted sleep is common in aging and is associated with cognition. Age-
related changes to sleep are associated with multiple causes, including early Alzheimer …

Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …

For optimal design of anti-amyloid-β (Aβ) and anti-tau clinical trials, we need to better
understand the pathophysiological cascade of Aβ-and tau-related processes. Therefore, we …